Literature DB >> 29941637

Ceftaroline Resistance by Clone-Specific Polymorphism in Penicillin-Binding Protein 2a of Methicillin-Resistant Staphylococcus aureus.

Hyukmin Lee1, Eun-Jeong Yoon1, Dokyun Kim1, Jung Wook Kim2, Kwang-Jun Lee2, Hyun Soo Kim3, Young Ree Kim4, Jong Hee Shin5, Jeong Hwan Shin6, Kyeong Seob Shin7, Young Ah Kim8, Young Uh9, Seok Hoon Jeong10.   

Abstract

A total of 281 nonduplicated Staphylococcus aureus blood isolates were collected from January to May 2017 from eight hospitals in South Korea to investigate the epidemiological traits of ceftaroline resistance in methicillin-resistant S. aureus (MRSA). Cefoxitin-disk diffusion tests and the mecA gene PCR revealed that 56.6% (159/281) of the S. aureus isolates were MRSA, and most belonged to ST5 (50.3%, 80/281) and ST72 (41.5%, 66/281). Of the MRSA isolates, 44.0% (70/159) were nonsusceptible to ceftaroline (MIC ≥ 2 mg/liter), whereas all of the methicillin-susceptible S. aureus isolates were susceptible to the drug. Eight amino acid substitutions in penicillin-binding protein 2a (PBP2a), including four (L357I, E447K, I563T, and S649A) in the penicillin-binding domain (PBD) and four (N104K, V117I, N146K, and A228V) in the non-PBD (nPBD) of PBP2a, were associated with ceftaroline resistance. The accumulation of substitutions in PBP2a resulted in the elevation of ceftaroline MICs: one substitution at 1 to 2 mg/liter, two or three substitutions at 2 to 4 mg/liter, and five substitutions at 4 or 16 mg/liter. Ceftaroline resistance in MRSA might be the result of clone-specific PBP2a polymorphism, along with substitutions both in PBD and nPBD, and the elevated ceftaroline MICs were associated with the substitution sites and accumulation of substitutions.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  ceftaroline; methicillin-resistant Staphylococcus aureus; non-penicillin-binding domain; penicillin-binding domain; penicillin-binding protein 2a

Mesh:

Substances:

Year:  2018        PMID: 29941637      PMCID: PMC6125543          DOI: 10.1128/AAC.00485-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Analysis of the genetic variability of genes encoding the RNA III-activating components Agr and TRAP in a population of Staphylococcus aureus strains isolated from cows with mastitis.

Authors:  Philippe Gilot; Gérard Lina; Thierry Cochard; Bernard Poutrel
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

2.  Missense mutations in PBP2A Affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998.

Authors:  William L Kelley; Ambre Jousselin; Christine Barras; Emmanuelle Lelong; Adriana Renzoni
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

3.  Combination of multiplex PCRs for staphylococcal cassette chromosome mec type assignment: rapid identification system for mec, ccr, and major differences in junkyard regions.

Authors:  Yoko Kondo; Teruyo Ito; Xiao Xue Ma; Shinya Watanabe; Barry N Kreiswirth; Jerome Etienne; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

4.  Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline.

Authors:  Rodrigo E Mendes; Athanassios Tsakris; Helio S Sader; Ronald N Jones; Donald Biek; Pamela McGhee; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  J Antimicrob Chemother       Date:  2012-03-07       Impact factor: 5.790

Review 5.  Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.

Authors:  Donald Biek; Ian A Critchley; Todd A Riccobene; Dirk A Thye
Journal:  J Antimicrob Chemother       Date:  2010-11       Impact factor: 5.790

6.  Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.

Authors:  G Ralph Corey; Mark Wilcox; George H Talbot; H David Friedland; Tanya Baculik; Gary W Witherell; Ian Critchley; Anita F Das; Dirk Thye
Journal:  Clin Infect Dis       Date:  2010-09-15       Impact factor: 9.079

7.  In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.

Authors:  Yigong Ge; Donald Biek; George H Talbot; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

8.  Missense mutations of PBP2a are associated with reduced susceptibility to ceftaroline and ceftobiprole in African MRSA.

Authors:  Frieder Schaumburg; Georg Peters; Abraham Alabi; Karsten Becker; Evgeny A Idelevich
Journal:  J Antimicrob Chemother       Date:  2015-10-05       Impact factor: 5.790

9.  In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program.

Authors:  Douglas J Biedenbach; Richard A Alm; Sushmita D Lahiri; Edina Reiszner; Daryl J Hoban; Daniel F Sahm; Samuel K Bouchillon; Jane E Ambler
Journal:  Antimicrob Agents Chemother       Date:  2015-10-26       Impact factor: 5.191

10.  Increasing Resistance to Extended-Spectrum Cephalosporins, Fluoroquinolone, and Carbapenem in Gram-Negative Bacilli and the Emergence of Carbapenem Non-Susceptibility in Klebsiella pneumoniae: Analysis of Korean Antimicrobial Resistance Monitoring System (KARMS) Data From 2013 to 2015.

Authors:  Dokyun Kim; Ji Young Ahn; Chae Hoon Lee; Sook Jin Jang; Hyukmin Lee; Dongeun Yong; Seok Hoon Jeong; Kyungwon Lee
Journal:  Ann Lab Med       Date:  2017-05       Impact factor: 3.464

View more
  7 in total

1.  Ability of Bicarbonate Supplementation To Sensitize Selected Methicillin-Resistant Staphylococcus aureus Strains to β-Lactam Antibiotics in an Ex Vivo Simulated Endocardial Vegetation Model.

Authors:  Arnold S Bayer; Selvi C Ersoy; Warren E Rose; Ana M Bienvenida; Yan Q Xiong; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

2.  Reduced Ceftaroline Susceptibility among Invasive MRSA Infections in Children: a Clinical and Genomic Investigation.

Authors:  J Chase McNeil; Lauren M Sommer; Jesus G Vallejo; Kristina G Hulten; Sheldon L Kaplan; Anthony R Flores
Journal:  Antimicrob Agents Chemother       Date:  2022-09-27       Impact factor: 5.938

3.  Antimicrobial Resistance and Clonal Lineages of Staphylococcus aureus from Cattle, Their Handlers, and Their Surroundings: A Cross-Sectional Study from the One Health Perspective.

Authors:  Vanessa Silva; Susana Correia; Jaqueline Rocha; Célia M Manaia; Adriana Silva; Juan García-Díez; José Eduardo Pereira; Teresa Semedo-Lemsaddek; Gilberto Igrejas; Patrícia Poeta
Journal:  Microorganisms       Date:  2022-04-30

Review 4.  Antimicrobial resistance in methicillin-resistant Staphylococcus aureus to newer antimicrobial agents.

Authors:  Richard R Watkins; Marisa Holubar; Michael Z David
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191

5.  A Multicenter Study To Evaluate Ceftaroline Breakpoints: Performance in an Area with High Prevalence of Methicillin-Resistant Staphylococcus aureus Sequence Type 5 Lineage.

Authors:  Ayesha Khan; Lina M Rivas; Maria Spencer; Rodrigo Martinez; Marusella Lam; Pamela Rojas; Lorena Porte; Francisco Silva; Stephanie Braun; Francisca Valdivieso; Margareta Mv Lhauser; Mónica Lafourcade; William R Miller; Patricia García; Cesar A Arias; Jose M Munita
Journal:  J Clin Microbiol       Date:  2019-08-26       Impact factor: 5.948

6.  Using genomics to understand meticillin- and vancomycin-resistant Staphylococcus aureus infections.

Authors:  Stefano G Giulieri; Steven Y C Tong; Deborah A Williamson
Journal:  Microb Genom       Date:  2020-01

Review 7.  Molecular Mechanisms of Drug Resistance in Staphylococcus aureus.

Authors:  Beata Mlynarczyk-Bonikowska; Cezary Kowalewski; Aneta Krolak-Ulinska; Wojciech Marusza
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.